Abstract 1788 Small Molecule Targeting of Atypical p38 Protects Against Viral Infection

Developing therapeutics that target the host kinome is a promising strategy to support current treatments for viral infections. While multiple direct-acting antivirals (DAAs) potentially clear Hepatitis C virus (HCV) infection in most individuals, ∼2.4 million individuals are unresponsive to the current DAAs or have secondary infections/complications that impact their treatment potential. Recent studies have shown that atypical p38 activity is critical for HCV replication and may have broader functions in regulating other viruses.